CT45A2: A Potential Drug Target and Biomarker for Cancer (G728911)

Target Name: CT45A2

NCBI ID: G728911

CT45A2

CT45A2: A Potential Drug Target and Biomarker for Cancer

CT45A2 is a protein that is expressed in various tissues, including the breast, lung, and gastrointestinal tract. It is a cell surface antigen that is associated with the development and progression of cancer. Specifically, CT45A2 is a glycoprotein that is expressed in high levels in cancer cells and has been shown to be involved in the development of several types of cancer, including breast, ovarian, and prostate cancer.

The potential drug targets for CT45A2 are numerous and varied. One of the most promising potential drug targets for CT45A2 is the inhibition of its cell surface antigens, such as CT45A2 itself. This can be achieved through various mechanisms, such as the use of small molecules, antibodies, or other therapeutic agents that target CT45A2 directly or indirectly.

Another potential drug target for CT45A2 is the inhibition of its signaling pathways. CT45A2 has been shown to play a role in several signaling pathways that are involved in cancer development, including the TGF-β pathway and the Wnt pathway. The inhibition of these pathways can be an effective way to target CT45A2 and prevent its role in cancer development.

In addition to its potential drug targets, CT45A2 also has the potential to serve as a biomarker for cancer. Its high expression levels in cancer cells make it an attractive candidate for use as a diagnostic or predictive marker. By measuring the levels of CT45A2 in cancer cells, doctors can determine the level of disease and guide treatment decisions. This can be particularly important in cases where the disease is aggressive and has high recurrence rates.

The development of new cancer treatments is a ongoing process, and CT45A2 is an promising candidate for drug targeting and biomarker use. As research continues to advance, the potential uses and benefits of CT45A2 will become clear. For now, however, it is important to recognize the potential of this protein and its role in the fight against cancer.

Protein Name: Cancer/testis Antigen Family 45 Member A2

The "CT45A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT45A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets